Shots:

• The P-III (VIVID-1) study assessed the safety & efficacy of mirikizumab (900mg, IV, Q4W, till wk.12 followed by 300mg, SC, Q4W from wks.12-52) vs PBO & ustekinumab (active control) for treating moderate to severe active Crohn's disease in adults
• Study depicted significantly improved histologic and histologic-endoscopic EPs at wks. 12 & 52, with 58.2% vs 48.8% of them achieving a histologic response. Among patients with prior biologic failure, 56.5% vs 41.3% achieved higher histologic response & 39.6% vs 27.8% achieved endoscopic-histologic response
• The company has submitted regulatory applications across various regions such as the US, EU, Japan & China, with additional submissions underway. Lilly is also conducting a UC trial to study 2 new EPs of bowel urgency frequency & deferral time, both affecting patients' QoL

Ref: PR Newswire | Image: Eli Lilly

Related News:- Eli Lilly’ Omvoh (mirikizumab-mrkz) Receives the US FDA’s Approval for Adults with Moderately to Severely Active Ulcerative Colitis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com